nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2A6—Fluorouracil—urinary bladder cancer	0.121	0.241	CbGbCtD
Montelukast—PTGS1—Etoposide—urinary bladder cancer	0.0866	0.172	CbGbCtD
Montelukast—CYP3A4—Thiotepa—urinary bladder cancer	0.0748	0.148	CbGbCtD
Montelukast—CYP2C8—Fluorouracil—urinary bladder cancer	0.0599	0.119	CbGbCtD
Montelukast—CYP2C8—Etoposide—urinary bladder cancer	0.05	0.0991	CbGbCtD
Montelukast—CYP2C9—Fluorouracil—urinary bladder cancer	0.0418	0.0829	CbGbCtD
Montelukast—CYP2C9—Cisplatin—urinary bladder cancer	0.0355	0.0704	CbGbCtD
Montelukast—CYP3A4—Etoposide—urinary bladder cancer	0.0203	0.0402	CbGbCtD
Montelukast—CYP3A4—Doxorubicin—urinary bladder cancer	0.0138	0.0274	CbGbCtD
Montelukast—CYSLTR1—prostate gland—urinary bladder cancer	0.0098	0.0911	CbGeAlD
Montelukast—CYP2C9—urine—urinary bladder cancer	0.00727	0.0675	CbGeAlD
Montelukast—CYSLTR1—smooth muscle tissue—urinary bladder cancer	0.00694	0.0645	CbGeAlD
Montelukast—ALOX5—prostate gland—urinary bladder cancer	0.00593	0.0551	CbGeAlD
Montelukast—CYP3A4—urine—urinary bladder cancer	0.00554	0.0515	CbGeAlD
Montelukast—CYSLTR1—female reproductive system—urinary bladder cancer	0.00535	0.0497	CbGeAlD
Montelukast—CYP2A6—prostate gland—urinary bladder cancer	0.00523	0.0486	CbGeAlD
Montelukast—CYSLTR1—vagina—urinary bladder cancer	0.00484	0.045	CbGeAlD
Montelukast—SLCO2B1—prostate gland—urinary bladder cancer	0.00457	0.0425	CbGeAlD
Montelukast—CYP2A6—seminal vesicle—urinary bladder cancer	0.00443	0.0411	CbGeAlD
Montelukast—ALOX5—smooth muscle tissue—urinary bladder cancer	0.0042	0.039	CbGeAlD
Montelukast—ALOX5—urethra—urinary bladder cancer	0.00397	0.0369	CbGeAlD
Montelukast—ALOX5—female reproductive system—urinary bladder cancer	0.00324	0.0301	CbGeAlD
Montelukast—CYSLTR1—lymph node—urinary bladder cancer	0.00313	0.0291	CbGeAlD
Montelukast—SLCO2B1—renal system—urinary bladder cancer	0.00311	0.0289	CbGeAlD
Montelukast—CYP2A6—vagina—urinary bladder cancer	0.00258	0.024	CbGeAlD
Montelukast—SLCO2B1—female reproductive system—urinary bladder cancer	0.00249	0.0232	CbGeAlD
Montelukast—PTGS1—prostate gland—urinary bladder cancer	0.00238	0.0221	CbGeAlD
Montelukast—PTGS1—seminal vesicle—urinary bladder cancer	0.00201	0.0187	CbGeAlD
Montelukast—CYP2C8—renal system—urinary bladder cancer	0.002	0.0186	CbGeAlD
Montelukast—ALOX5—lymph node—urinary bladder cancer	0.00189	0.0176	CbGeAlD
Montelukast—PTGS1—epithelium—urinary bladder cancer	0.00175	0.0163	CbGeAlD
Montelukast—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00169	0.0157	CbGeAlD
Montelukast—PTGS1—renal system—urinary bladder cancer	0.00162	0.0151	CbGeAlD
Montelukast—CYP2C8—female reproductive system—urinary bladder cancer	0.0016	0.0149	CbGeAlD
Montelukast—SLCO2B1—lymph node—urinary bladder cancer	0.00146	0.0136	CbGeAlD
Montelukast—CYP2C8—vagina—urinary bladder cancer	0.00145	0.0135	CbGeAlD
Montelukast—CYP2C9—female reproductive system—urinary bladder cancer	0.00142	0.0132	CbGeAlD
Montelukast—CYP3A4—renal system—urinary bladder cancer	0.00136	0.0126	CbGeAlD
Montelukast—PTGS1—female reproductive system—urinary bladder cancer	0.0013	0.0121	CbGeAlD
Montelukast—PTGS1—vagina—urinary bladder cancer	0.00118	0.0109	CbGeAlD
Montelukast—CYP3A4—female reproductive system—urinary bladder cancer	0.00109	0.0101	CbGeAlD
Montelukast—PTGS1—lymph node—urinary bladder cancer	0.000761	0.00707	CbGeAlD
Montelukast—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000418	0.00169	CcSEcCtD
Montelukast—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000418	0.00168	CcSEcCtD
Montelukast—Infection—Etoposide—urinary bladder cancer	0.000418	0.00168	CcSEcCtD
Montelukast—Influenza—Epirubicin—urinary bladder cancer	0.000415	0.00167	CcSEcCtD
Montelukast—Asthma—Epirubicin—urinary bladder cancer	0.000415	0.00167	CcSEcCtD
Montelukast—Pruritus—Thiotepa—urinary bladder cancer	0.000414	0.00167	CcSEcCtD
Montelukast—Pain—Fluorouracil—urinary bladder cancer	0.000414	0.00167	CcSEcCtD
Montelukast—Paraesthesia—Cisplatin—urinary bladder cancer	0.000412	0.00166	CcSEcCtD
Montelukast—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000412	0.00166	CcSEcCtD
Montelukast—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000412	0.00166	CcSEcCtD
Montelukast—Eosinophilia—Epirubicin—urinary bladder cancer	0.000411	0.00165	CcSEcCtD
Montelukast—Skin disorder—Etoposide—urinary bladder cancer	0.000409	0.00165	CcSEcCtD
Montelukast—Pancreatitis—Epirubicin—urinary bladder cancer	0.000407	0.00164	CcSEcCtD
Montelukast—Diarrhoea—Thiotepa—urinary bladder cancer	0.000401	0.00161	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.0004	0.00161	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.0004	0.00161	CcSEcCtD
Montelukast—Bronchitis—Epirubicin—urinary bladder cancer	0.000399	0.00161	CcSEcCtD
Montelukast—Pneumonia—Methotrexate—urinary bladder cancer	0.000397	0.0016	CcSEcCtD
Montelukast—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000397	0.0016	CcSEcCtD
Montelukast—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000396	0.0016	CcSEcCtD
Montelukast—Drowsiness—Methotrexate—urinary bladder cancer	0.000395	0.00159	CcSEcCtD
Montelukast—Infestation—Methotrexate—urinary bladder cancer	0.000395	0.00159	CcSEcCtD
Montelukast—Infestation NOS—Methotrexate—urinary bladder cancer	0.000395	0.00159	CcSEcCtD
Montelukast—Pain—Cisplatin—urinary bladder cancer	0.000393	0.00158	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000392	0.00158	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000392	0.00158	CcSEcCtD
Montelukast—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000389	0.00157	CcSEcCtD
Montelukast—Dizziness—Thiotepa—urinary bladder cancer	0.000387	0.00156	CcSEcCtD
Montelukast—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000385	0.00155	CcSEcCtD
Montelukast—Urticaria—Fluorouracil—urinary bladder cancer	0.000385	0.00155	CcSEcCtD
Montelukast—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000384	0.00155	CcSEcCtD
Montelukast—Influenza—Doxorubicin—urinary bladder cancer	0.000384	0.00155	CcSEcCtD
Montelukast—Asthma—Doxorubicin—urinary bladder cancer	0.000384	0.00155	CcSEcCtD
Montelukast—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000383	0.00154	CcSEcCtD
Montelukast—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00038	0.00153	CcSEcCtD
Montelukast—Paraesthesia—Etoposide—urinary bladder cancer	0.000378	0.00152	CcSEcCtD
Montelukast—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000376	0.00152	CcSEcCtD
Montelukast—Somnolence—Etoposide—urinary bladder cancer	0.000374	0.00151	CcSEcCtD
Montelukast—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000374	0.00151	CcSEcCtD
Montelukast—Epistaxis—Methotrexate—urinary bladder cancer	0.000373	0.0015	CcSEcCtD
Montelukast—Vomiting—Thiotepa—urinary bladder cancer	0.000372	0.0015	CcSEcCtD
Montelukast—Pneumonia—Epirubicin—urinary bladder cancer	0.000372	0.0015	CcSEcCtD
Montelukast—Infestation NOS—Epirubicin—urinary bladder cancer	0.00037	0.00149	CcSEcCtD
Montelukast—Infestation—Epirubicin—urinary bladder cancer	0.00037	0.00149	CcSEcCtD
Montelukast—Drowsiness—Epirubicin—urinary bladder cancer	0.00037	0.00149	CcSEcCtD
Montelukast—Rash—Thiotepa—urinary bladder cancer	0.000369	0.00149	CcSEcCtD
Montelukast—Bronchitis—Doxorubicin—urinary bladder cancer	0.000369	0.00149	CcSEcCtD
Montelukast—Dermatitis—Thiotepa—urinary bladder cancer	0.000369	0.00149	CcSEcCtD
Montelukast—Headache—Thiotepa—urinary bladder cancer	0.000367	0.00148	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000367	0.00148	CcSEcCtD
Montelukast—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000363	0.00146	CcSEcCtD
Montelukast—Body temperature increased—Cisplatin—urinary bladder cancer	0.000363	0.00146	CcSEcCtD
Montelukast—Fatigue—Etoposide—urinary bladder cancer	0.000363	0.00146	CcSEcCtD
Montelukast—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000362	0.00146	CcSEcCtD
Montelukast—Jaundice—Epirubicin—urinary bladder cancer	0.00036	0.00145	CcSEcCtD
Montelukast—Pain—Etoposide—urinary bladder cancer	0.00036	0.00145	CcSEcCtD
Montelukast—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000359	0.00145	CcSEcCtD
Montelukast—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000357	0.00144	CcSEcCtD
Montelukast—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000357	0.00144	CcSEcCtD
Montelukast—Hepatitis—Methotrexate—urinary bladder cancer	0.000355	0.00143	CcSEcCtD
Montelukast—Asthenia—Gemcitabine—urinary bladder cancer	0.000353	0.00142	CcSEcCtD
Montelukast—Pharyngitis—Methotrexate—urinary bladder cancer	0.000352	0.00142	CcSEcCtD
Montelukast—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00035	0.00141	CcSEcCtD
Montelukast—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00035	0.00141	CcSEcCtD
Montelukast—Epistaxis—Epirubicin—urinary bladder cancer	0.000349	0.00141	CcSEcCtD
Montelukast—Pruritus—Gemcitabine—urinary bladder cancer	0.000349	0.0014	CcSEcCtD
Montelukast—Nausea—Thiotepa—urinary bladder cancer	0.000348	0.0014	CcSEcCtD
Montelukast—Urethral disorder—Methotrexate—urinary bladder cancer	0.000348	0.0014	CcSEcCtD
Montelukast—Sinusitis—Epirubicin—urinary bladder cancer	0.000347	0.0014	CcSEcCtD
Montelukast—Pneumonia—Doxorubicin—urinary bladder cancer	0.000344	0.00139	CcSEcCtD
Montelukast—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000344	0.00139	CcSEcCtD
Montelukast—Pruritus—Fluorouracil—urinary bladder cancer	0.000343	0.00138	CcSEcCtD
Montelukast—Infestation—Doxorubicin—urinary bladder cancer	0.000342	0.00138	CcSEcCtD
Montelukast—Drowsiness—Doxorubicin—urinary bladder cancer	0.000342	0.00138	CcSEcCtD
Montelukast—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000342	0.00138	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000339	0.00137	CcSEcCtD
Montelukast—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000338	0.00136	CcSEcCtD
Montelukast—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000337	0.00136	CcSEcCtD
Montelukast—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000335	0.00135	CcSEcCtD
Montelukast—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000335	0.00135	CcSEcCtD
Montelukast—Urticaria—Etoposide—urinary bladder cancer	0.000334	0.00135	CcSEcCtD
Montelukast—Jaundice—Doxorubicin—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Montelukast—Rhinitis—Epirubicin—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Montelukast—Abdominal pain—Etoposide—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Montelukast—Body temperature increased—Etoposide—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Montelukast—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Montelukast—Hepatitis—Epirubicin—urinary bladder cancer	0.000332	0.00134	CcSEcCtD
Montelukast—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000331	0.00134	CcSEcCtD
Montelukast—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00033	0.00133	CcSEcCtD
Montelukast—Asthenia—Cisplatin—urinary bladder cancer	0.000329	0.00133	CcSEcCtD
Montelukast—Pharyngitis—Epirubicin—urinary bladder cancer	0.000329	0.00133	CcSEcCtD
Montelukast—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000329	0.00133	CcSEcCtD
Montelukast—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000328	0.00132	CcSEcCtD
Montelukast—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000326	0.00131	CcSEcCtD
Montelukast—Urethral disorder—Epirubicin—urinary bladder cancer	0.000325	0.00131	CcSEcCtD
Montelukast—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000324	0.0013	CcSEcCtD
Montelukast—Epistaxis—Doxorubicin—urinary bladder cancer	0.000323	0.0013	CcSEcCtD
Montelukast—Sinusitis—Doxorubicin—urinary bladder cancer	0.000321	0.00129	CcSEcCtD
Montelukast—Immune system disorder—Methotrexate—urinary bladder cancer	0.00032	0.00129	CcSEcCtD
Montelukast—Dizziness—Fluorouracil—urinary bladder cancer	0.00032	0.00129	CcSEcCtD
Montelukast—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00032	0.00129	CcSEcCtD
Montelukast—Diarrhoea—Cisplatin—urinary bladder cancer	0.000314	0.00127	CcSEcCtD
Montelukast—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000314	0.00126	CcSEcCtD
Montelukast—Vomiting—Gemcitabine—urinary bladder cancer	0.000313	0.00126	CcSEcCtD
Montelukast—Mental disorder—Methotrexate—urinary bladder cancer	0.000311	0.00125	CcSEcCtD
Montelukast—Rash—Gemcitabine—urinary bladder cancer	0.000311	0.00125	CcSEcCtD
Montelukast—Dermatitis—Gemcitabine—urinary bladder cancer	0.00031	0.00125	CcSEcCtD
Montelukast—Hypersensitivity—Etoposide—urinary bladder cancer	0.00031	0.00125	CcSEcCtD
Montelukast—Headache—Gemcitabine—urinary bladder cancer	0.000309	0.00124	CcSEcCtD
Montelukast—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000308	0.00124	CcSEcCtD
Montelukast—Vomiting—Fluorouracil—urinary bladder cancer	0.000308	0.00124	CcSEcCtD
Montelukast—Rhinitis—Doxorubicin—urinary bladder cancer	0.000308	0.00124	CcSEcCtD
Montelukast—Hepatitis—Doxorubicin—urinary bladder cancer	0.000307	0.00124	CcSEcCtD
Montelukast—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000306	0.00123	CcSEcCtD
Montelukast—Rash—Fluorouracil—urinary bladder cancer	0.000305	0.00123	CcSEcCtD
Montelukast—Dermatitis—Fluorouracil—urinary bladder cancer	0.000305	0.00123	CcSEcCtD
Montelukast—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000305	0.00123	CcSEcCtD
Montelukast—Headache—Fluorouracil—urinary bladder cancer	0.000303	0.00122	CcSEcCtD
Montelukast—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000303	0.00122	CcSEcCtD
Montelukast—Asthenia—Etoposide—urinary bladder cancer	0.000302	0.00122	CcSEcCtD
Montelukast—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000302	0.00122	CcSEcCtD
Montelukast—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000301	0.00121	CcSEcCtD
Montelukast—Immune system disorder—Epirubicin—urinary bladder cancer	0.0003	0.00121	CcSEcCtD
Montelukast—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000299	0.00121	CcSEcCtD
Montelukast—Pruritus—Etoposide—urinary bladder cancer	0.000298	0.0012	CcSEcCtD
Montelukast—Nausea—Gemcitabine—urinary bladder cancer	0.000293	0.00118	CcSEcCtD
Montelukast—Vomiting—Cisplatin—urinary bladder cancer	0.000292	0.00118	CcSEcCtD
Montelukast—Mental disorder—Epirubicin—urinary bladder cancer	0.000291	0.00117	CcSEcCtD
Montelukast—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00029	0.00117	CcSEcCtD
Montelukast—Rash—Cisplatin—urinary bladder cancer	0.00029	0.00117	CcSEcCtD
Montelukast—Dermatitis—Cisplatin—urinary bladder cancer	0.000289	0.00117	CcSEcCtD
Montelukast—Diarrhoea—Etoposide—urinary bladder cancer	0.000288	0.00116	CcSEcCtD
Montelukast—Nausea—Fluorouracil—urinary bladder cancer	0.000288	0.00116	CcSEcCtD
Montelukast—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000285	0.00115	CcSEcCtD
Montelukast—Dizziness—Etoposide—urinary bladder cancer	0.000278	0.00112	CcSEcCtD
Montelukast—Muscle spasms—Epirubicin—urinary bladder cancer	0.000278	0.00112	CcSEcCtD
Montelukast—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000277	0.00112	CcSEcCtD
Montelukast—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000277	0.00112	CcSEcCtD
Montelukast—Nausea—Cisplatin—urinary bladder cancer	0.000273	0.0011	CcSEcCtD
Montelukast—Cough—Methotrexate—urinary bladder cancer	0.000269	0.00109	CcSEcCtD
Montelukast—Mental disorder—Doxorubicin—urinary bladder cancer	0.000269	0.00108	CcSEcCtD
Montelukast—Convulsion—Methotrexate—urinary bladder cancer	0.000267	0.00108	CcSEcCtD
Montelukast—Vomiting—Etoposide—urinary bladder cancer	0.000267	0.00108	CcSEcCtD
Montelukast—Agitation—Epirubicin—urinary bladder cancer	0.000266	0.00107	CcSEcCtD
Montelukast—Rash—Etoposide—urinary bladder cancer	0.000265	0.00107	CcSEcCtD
Montelukast—Dermatitis—Etoposide—urinary bladder cancer	0.000265	0.00107	CcSEcCtD
Montelukast—Headache—Etoposide—urinary bladder cancer	0.000264	0.00106	CcSEcCtD
Montelukast—Arthralgia—Methotrexate—urinary bladder cancer	0.000263	0.00106	CcSEcCtD
Montelukast—Myalgia—Methotrexate—urinary bladder cancer	0.000263	0.00106	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000261	0.00105	CcSEcCtD
Montelukast—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000257	0.00104	CcSEcCtD
Montelukast—Palpitations—Epirubicin—urinary bladder cancer	0.000255	0.00103	CcSEcCtD
Montelukast—Cough—Epirubicin—urinary bladder cancer	0.000252	0.00102	CcSEcCtD
Montelukast—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000252	0.00102	CcSEcCtD
Montelukast—Convulsion—Epirubicin—urinary bladder cancer	0.00025	0.00101	CcSEcCtD
Montelukast—Infection—Methotrexate—urinary bladder cancer	0.00025	0.00101	CcSEcCtD
Montelukast—Nausea—Etoposide—urinary bladder cancer	0.00025	0.00101	CcSEcCtD
Montelukast—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000247	0.000996	CcSEcCtD
Montelukast—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000247	0.000994	CcSEcCtD
Montelukast—Arthralgia—Epirubicin—urinary bladder cancer	0.000246	0.000991	CcSEcCtD
Montelukast—Myalgia—Epirubicin—urinary bladder cancer	0.000246	0.000991	CcSEcCtD
Montelukast—Agitation—Doxorubicin—urinary bladder cancer	0.000246	0.00099	CcSEcCtD
Montelukast—Anxiety—Epirubicin—urinary bladder cancer	0.000245	0.000988	CcSEcCtD
Montelukast—Skin disorder—Methotrexate—urinary bladder cancer	0.000245	0.000986	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000244	0.000984	CcSEcCtD
Montelukast—Palpitations—Doxorubicin—urinary bladder cancer	0.000236	0.000952	CcSEcCtD
Montelukast—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000236	0.00095	CcSEcCtD
Montelukast—Oedema—Epirubicin—urinary bladder cancer	0.000236	0.00095	CcSEcCtD
Montelukast—Infection—Epirubicin—urinary bladder cancer	0.000234	0.000944	CcSEcCtD
Montelukast—Cough—Doxorubicin—urinary bladder cancer	0.000233	0.00094	CcSEcCtD
Montelukast—Convulsion—Doxorubicin—urinary bladder cancer	0.000232	0.000933	CcSEcCtD
Montelukast—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000231	0.000932	CcSEcCtD
Montelukast—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000231	0.00093	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00023	0.000925	CcSEcCtD
Montelukast—Skin disorder—Epirubicin—urinary bladder cancer	0.000229	0.000923	CcSEcCtD
Montelukast—Insomnia—Methotrexate—urinary bladder cancer	0.000228	0.000918	CcSEcCtD
Montelukast—Myalgia—Doxorubicin—urinary bladder cancer	0.000228	0.000917	CcSEcCtD
Montelukast—Arthralgia—Doxorubicin—urinary bladder cancer	0.000228	0.000917	CcSEcCtD
Montelukast—Anxiety—Doxorubicin—urinary bladder cancer	0.000227	0.000914	CcSEcCtD
Montelukast—Paraesthesia—Methotrexate—urinary bladder cancer	0.000226	0.000912	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000226	0.000911	CcSEcCtD
Montelukast—Somnolence—Methotrexate—urinary bladder cancer	0.000224	0.000903	CcSEcCtD
Montelukast—Dyspepsia—Methotrexate—urinary bladder cancer	0.000222	0.000894	CcSEcCtD
Montelukast—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000218	0.000879	CcSEcCtD
Montelukast—Oedema—Doxorubicin—urinary bladder cancer	0.000218	0.000879	CcSEcCtD
Montelukast—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000218	0.000876	CcSEcCtD
Montelukast—Fatigue—Methotrexate—urinary bladder cancer	0.000217	0.000875	CcSEcCtD
Montelukast—Infection—Doxorubicin—urinary bladder cancer	0.000217	0.000873	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000216	0.00154	CbGpPWpGaD
Montelukast—Pain—Methotrexate—urinary bladder cancer	0.000215	0.000868	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000215	0.000866	CcSEcCtD
Montelukast—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000214	0.000862	CcSEcCtD
Montelukast—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000214	0.000861	CcSEcCtD
Montelukast—Insomnia—Epirubicin—urinary bladder cancer	0.000213	0.000859	CcSEcCtD
Montelukast—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000213	0.00152	CbGpPWpGaD
Montelukast—Skin disorder—Doxorubicin—urinary bladder cancer	0.000212	0.000854	CcSEcCtD
Montelukast—Paraesthesia—Epirubicin—urinary bladder cancer	0.000212	0.000853	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000211	0.00151	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.00021	0.0015	CbGpPWpGaD
Montelukast—Somnolence—Epirubicin—urinary bladder cancer	0.00021	0.000845	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000209	0.00149	CbGpPWpGaD
Montelukast—Dyspepsia—Epirubicin—urinary bladder cancer	0.000208	0.000836	CcSEcCtD
Montelukast—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000206	0.00083	CcSEcCtD
Montelukast—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000205	0.00147	CbGpPWpGaD
Montelukast—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000204	0.00082	CcSEcCtD
Montelukast—Fatigue—Epirubicin—urinary bladder cancer	0.000203	0.000819	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000202	0.00144	CbGpPWpGaD
Montelukast—Pain—Epirubicin—urinary bladder cancer	0.000202	0.000812	CcSEcCtD
Montelukast—Urticaria—Methotrexate—urinary bladder cancer	0.0002	0.000807	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—GLI1—urinary bladder cancer	0.0002	0.00143	CbGpPWpGaD
Montelukast—Body temperature increased—Methotrexate—urinary bladder cancer	0.000199	0.000803	CcSEcCtD
Montelukast—Abdominal pain—Methotrexate—urinary bladder cancer	0.000199	0.000803	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000199	0.000801	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000198	0.00142	CbGpPWpGaD
Montelukast—Insomnia—Doxorubicin—urinary bladder cancer	0.000197	0.000795	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000197	0.00141	CbGpPWpGaD
Montelukast—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000196	0.000789	CcSEcCtD
Montelukast—Somnolence—Doxorubicin—urinary bladder cancer	0.000194	0.000782	CcSEcCtD
Montelukast—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000193	0.000777	CcSEcCtD
Montelukast—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000192	0.000774	CcSEcCtD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000191	0.00136	CbGpPWpGaD
Montelukast—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000188	0.000759	CcSEcCtD
Montelukast—Fatigue—Doxorubicin—urinary bladder cancer	0.000188	0.000758	CcSEcCtD
Montelukast—Urticaria—Epirubicin—urinary bladder cancer	0.000187	0.000755	CcSEcCtD
Montelukast—Pain—Doxorubicin—urinary bladder cancer	0.000187	0.000752	CcSEcCtD
Montelukast—Abdominal pain—Epirubicin—urinary bladder cancer	0.000186	0.000751	CcSEcCtD
Montelukast—Body temperature increased—Epirubicin—urinary bladder cancer	0.000186	0.000751	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000186	0.00133	CbGpPWpGaD
Montelukast—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000186	0.000748	CcSEcCtD
Montelukast—ALOX5—Metabolism—TYMP—urinary bladder cancer	0.000185	0.00132	CbGpPWpGaD
Montelukast—Asthenia—Methotrexate—urinary bladder cancer	0.000181	0.000728	CcSEcCtD
Montelukast—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000179	0.00127	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000178	0.000719	CcSEcCtD
Montelukast—Pruritus—Methotrexate—urinary bladder cancer	0.000178	0.000718	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000178	0.00127	CbGpPWpGaD
Montelukast—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000174	0.0007	CcSEcCtD
Montelukast—Urticaria—Doxorubicin—urinary bladder cancer	0.000173	0.000698	CcSEcCtD
Montelukast—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000173	0.00124	CbGpPWpGaD
Montelukast—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000172	0.000695	CcSEcCtD
Montelukast—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000172	0.000695	CcSEcCtD
Montelukast—Diarrhoea—Methotrexate—urinary bladder cancer	0.000172	0.000695	CcSEcCtD
Montelukast—Asthenia—Epirubicin—urinary bladder cancer	0.000169	0.000682	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000168	0.0012	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—NAT2—urinary bladder cancer	0.000168	0.0012	CbGpPWpGaD
Montelukast—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000167	0.00119	CbGpPWpGaD
Montelukast—Pruritus—Epirubicin—urinary bladder cancer	0.000167	0.000672	CcSEcCtD
Montelukast—Dizziness—Methotrexate—urinary bladder cancer	0.000167	0.000671	CcSEcCtD
Montelukast—Diarrhoea—Epirubicin—urinary bladder cancer	0.000161	0.00065	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000161	0.00115	CbGpPWpGaD
Montelukast—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000161	0.000648	CcSEcCtD
Montelukast—Vomiting—Methotrexate—urinary bladder cancer	0.00016	0.000645	CcSEcCtD
Montelukast—Rash—Methotrexate—urinary bladder cancer	0.000159	0.00064	CcSEcCtD
Montelukast—Dermatitis—Methotrexate—urinary bladder cancer	0.000159	0.00064	CcSEcCtD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000158	0.00113	CbGpPWpGaD
Montelukast—Headache—Methotrexate—urinary bladder cancer	0.000158	0.000636	CcSEcCtD
Montelukast—Asthenia—Doxorubicin—urinary bladder cancer	0.000157	0.000631	CcSEcCtD
Montelukast—Dizziness—Epirubicin—urinary bladder cancer	0.000156	0.000628	CcSEcCtD
Montelukast—Pruritus—Doxorubicin—urinary bladder cancer	0.000154	0.000622	CcSEcCtD
Montelukast—Vomiting—Epirubicin—urinary bladder cancer	0.00015	0.000604	CcSEcCtD
Montelukast—Nausea—Methotrexate—urinary bladder cancer	0.00015	0.000603	CcSEcCtD
Montelukast—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000149	0.000601	CcSEcCtD
Montelukast—Rash—Epirubicin—urinary bladder cancer	0.000149	0.000599	CcSEcCtD
Montelukast—Dermatitis—Epirubicin—urinary bladder cancer	0.000149	0.000598	CcSEcCtD
Montelukast—Headache—Epirubicin—urinary bladder cancer	0.000148	0.000595	CcSEcCtD
Montelukast—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000147	0.00105	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000147	0.00105	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000145	0.00104	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000145	0.00104	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—RRM2—urinary bladder cancer	0.000145	0.00103	CbGpPWpGaD
Montelukast—Dizziness—Doxorubicin—urinary bladder cancer	0.000144	0.000581	CcSEcCtD
Montelukast—Nausea—Epirubicin—urinary bladder cancer	0.00014	0.000564	CcSEcCtD
Montelukast—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	0.00014	0.000999	CbGpPWpGaD
Montelukast—Vomiting—Doxorubicin—urinary bladder cancer	0.000139	0.000559	CcSEcCtD
Montelukast—Rash—Doxorubicin—urinary bladder cancer	0.000138	0.000554	CcSEcCtD
Montelukast—Dermatitis—Doxorubicin—urinary bladder cancer	0.000137	0.000554	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—RBX1—urinary bladder cancer	0.000137	0.000978	CbGpPWpGaD
Montelukast—Headache—Doxorubicin—urinary bladder cancer	0.000137	0.000551	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000136	0.000975	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000136	0.000968	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ENO2—urinary bladder cancer	0.000134	0.000956	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—HPGDS—urinary bladder cancer	0.000134	0.000956	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000134	0.000954	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000133	0.000951	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTO2—urinary bladder cancer	0.000133	0.000947	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NAT1—urinary bladder cancer	0.000133	0.000947	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.000132	0.000944	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00013	0.000931	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTT1—urinary bladder cancer	0.00013	0.000928	CbGpPWpGaD
Montelukast—Nausea—Doxorubicin—urinary bladder cancer	0.00013	0.000522	CcSEcCtD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000129	0.00092	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TSC1—urinary bladder cancer	0.000129	0.00092	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000128	0.000913	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	0.000125	0.000895	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NAT1—urinary bladder cancer	0.000125	0.000895	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000123	0.000875	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	0.000121	0.000866	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.00012	0.000857	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000118	0.000845	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000118	0.000841	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	0.000115	0.000819	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000114	0.000815	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000113	0.000807	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.00011	0.000788	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	0.000109	0.00078	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000109	0.000777	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—NQO1—urinary bladder cancer	0.000108	0.000771	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000105	0.000748	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000104	0.00074	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	0.000103	0.000737	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	0.000103	0.000736	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PRSS3—urinary bladder cancer	0.0001	0.000717	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—S100B—urinary bladder cancer	9.93e-05	0.000709	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	9.75e-05	0.000696	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	9.5e-05	0.000678	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—RHOA—urinary bladder cancer	9.41e-05	0.000672	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.13e-05	0.000652	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.1e-05	0.00065	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	9.03e-05	0.000645	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTP1—urinary bladder cancer	9e-05	0.000643	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NCOR1—urinary bladder cancer	8.93e-05	0.000637	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.71e-05	0.000622	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—IL2—urinary bladder cancer	8.7e-05	0.000621	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	8.56e-05	0.000611	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NAT1—urinary bladder cancer	8.56e-05	0.000611	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.42e-05	0.000601	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—TYMS—urinary bladder cancer	8.37e-05	0.000598	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—NCOR1—urinary bladder cancer	8.27e-05	0.000591	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTM1—urinary bladder cancer	8.27e-05	0.000591	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	8.26e-05	0.00059	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.06e-05	0.000575	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—TYMP—urinary bladder cancer	8.03e-05	0.000574	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GPX1—urinary bladder cancer	7.92e-05	0.000566	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	7.92e-05	0.000565	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL2—urinary bladder cancer	7.9e-05	0.000564	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TERT—urinary bladder cancer	7.87e-05	0.000562	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	7.83e-05	0.000559	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.81e-05	0.000557	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ERCC2—urinary bladder cancer	7.78e-05	0.000555	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.72e-05	0.000551	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—TYMP—urinary bladder cancer	7.6e-05	0.000542	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	7.35e-05	0.000525	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—MTHFR—urinary bladder cancer	7.31e-05	0.000522	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.27e-05	0.000519	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NAT2—urinary bladder cancer	7.26e-05	0.000519	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—FGFR3—urinary bladder cancer	7.22e-05	0.000515	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.17e-05	0.000512	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	7.05e-05	0.000504	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ESR1—urinary bladder cancer	7.01e-05	0.000501	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	6.97e-05	0.000498	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NAT1—urinary bladder cancer	6.97e-05	0.000498	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NAT2—urinary bladder cancer	6.87e-05	0.00049	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.86e-05	0.000489	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	6.66e-05	0.000476	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	6.49e-05	0.000463	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	6.37e-05	0.000455	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—RRM2—urinary bladder cancer	6.27e-05	0.000448	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CREBBP—urinary bladder cancer	6.15e-05	0.000439	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IGF1—urinary bladder cancer	6.07e-05	0.000433	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—EGFR—urinary bladder cancer	6.04e-05	0.000431	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PPARG—urinary bladder cancer	5.93e-05	0.000423	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—RRM2—urinary bladder cancer	5.93e-05	0.000423	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—HPGDS—urinary bladder cancer	5.81e-05	0.000415	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ENO2—urinary bladder cancer	5.81e-05	0.000415	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.77e-05	0.000412	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	5.74e-05	0.00041	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—KRAS—urinary bladder cancer	5.71e-05	0.000407	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CREBBP—urinary bladder cancer	5.7e-05	0.000407	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTT1—urinary bladder cancer	5.63e-05	0.000402	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RHOA—urinary bladder cancer	5.56e-05	0.000397	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.55e-05	0.000396	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ENO2—urinary bladder cancer	5.49e-05	0.000392	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	5.49e-05	0.000392	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	5.42e-05	0.000387	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	5.33e-05	0.00038	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	5.28e-05	0.000377	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.2e-05	0.000372	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—TYMP—urinary bladder cancer	5.19e-05	0.00037	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ERBB2—urinary bladder cancer	5.15e-05	0.000367	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.98e-05	0.000356	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL8—urinary bladder cancer	4.88e-05	0.000348	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—HRAS—urinary bladder cancer	4.85e-05	0.000346	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.85e-05	0.000346	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NAT2—urinary bladder cancer	4.69e-05	0.000335	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NQO1—urinary bladder cancer	4.68e-05	0.000334	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTGS2—urinary bladder cancer	4.66e-05	0.000333	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL2—urinary bladder cancer	4.66e-05	0.000333	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.6e-05	0.000328	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.6e-05	0.000328	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCND1—urinary bladder cancer	4.55e-05	0.000325	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.54e-05	0.000324	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NQO1—urinary bladder cancer	4.43e-05	0.000316	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MMP9—urinary bladder cancer	4.41e-05	0.000315	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.4e-05	0.000314	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTEN—urinary bladder cancer	4.39e-05	0.000313	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.24e-05	0.000302	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.22e-05	0.000302	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.2e-05	0.0003	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EP300—urinary bladder cancer	4.19e-05	0.000299	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SRC—urinary bladder cancer	4.07e-05	0.000291	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTEN—urinary bladder cancer	4.07e-05	0.00029	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.06e-05	0.00029	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.05e-05	0.000289	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.96e-05	0.000283	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTP1—urinary bladder cancer	3.9e-05	0.000279	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—EP300—urinary bladder cancer	3.88e-05	0.000277	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.82e-05	0.000273	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.79e-05	0.00027	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.78e-05	0.00027	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	3.75e-05	0.000268	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ENO2—urinary bladder cancer	3.75e-05	0.000268	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.73e-05	0.000266	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	3.69e-05	0.000264	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MYC—urinary bladder cancer	3.65e-05	0.00026	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	3.64e-05	0.00026	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—TYMS—urinary bladder cancer	3.63e-05	0.000259	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NCOR1—urinary bladder cancer	3.59e-05	0.000256	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTM1—urinary bladder cancer	3.59e-05	0.000256	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.58e-05	0.000256	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.57e-05	0.000255	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EGFR—urinary bladder cancer	3.57e-05	0.000255	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.48e-05	0.000249	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GPX1—urinary bladder cancer	3.44e-05	0.000245	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—TYMS—urinary bladder cancer	3.43e-05	0.000245	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	3.39e-05	0.000242	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	3.39e-05	0.000242	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ERCC2—urinary bladder cancer	3.37e-05	0.000241	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—KRAS—urinary bladder cancer	3.37e-05	0.000241	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.3e-05	0.000235	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GPX1—urinary bladder cancer	3.25e-05	0.000232	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	3.19e-05	0.000228	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—MTHFR—urinary bladder cancer	3.17e-05	0.000226	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.05e-05	0.000218	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.05e-05	0.000218	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.04e-05	0.000217	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.02e-05	0.000216	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	3e-05	0.000214	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—urinary bladder cancer	3e-05	0.000214	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.96e-05	0.000211	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.93e-05	0.000209	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.92e-05	0.000208	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HRAS—urinary bladder cancer	2.86e-05	0.000205	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.79e-05	0.000199	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PPARG—urinary bladder cancer	2.57e-05	0.000184	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.56e-05	0.000183	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.52e-05	0.00018	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.52e-05	0.00018	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CREBBP—urinary bladder cancer	2.47e-05	0.000176	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.46e-05	0.000176	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.44e-05	0.000174	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PPARG—urinary bladder cancer	2.43e-05	0.000174	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.39e-05	0.00017	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.34e-05	0.000167	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	2.34e-05	0.000167	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.32e-05	0.000165	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.32e-05	0.000165	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.22e-05	0.000158	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.18e-05	0.000156	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.17e-05	0.000155	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.08e-05	0.000149	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.05e-05	0.000147	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.05e-05	0.000146	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTGS2—urinary bladder cancer	2.02e-05	0.000144	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.01e-05	0.000144	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.01e-05	0.000144	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.99e-05	0.000142	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.95e-05	0.000139	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	1.91e-05	0.000137	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.91e-05	0.000136	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.89e-05	0.000135	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.89e-05	0.000135	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.77e-05	0.000127	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.76e-05	0.000126	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—EP300—urinary bladder cancer	1.68e-05	0.00012	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTEN—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.66e-05	0.000119	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.62e-05	0.000116	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.6e-05	0.000114	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—EP300—urinary bladder cancer	1.59e-05	0.000114	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.35e-05	9.67e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.35e-05	9.65e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.31e-05	9.33e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.3e-05	9.27e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.26e-05	8.99e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.24e-05	8.88e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.24e-05	8.88e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.19e-05	8.51e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.17e-05	8.35e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.14e-05	8.14e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.1e-05	7.85e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.09e-05	7.76e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.06e-05	7.59e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.27e-06	6.62e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.91e-06	6.37e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—EP300—urinary bladder cancer	8.84e-06	6.31e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.56e-06	6.11e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.01e-06	5.01e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.12e-06	4.37e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.83e-06	4.16e-05	CbGpPWpGaD
